Neon Therapeutics News Releases https://ir.neontherapeutics.com/ Neon Therapeutics News Releases en Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-reports-first-quarter-2019-financial-results Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine Expect to report in July top-line clinical results, including 12-month follow-up, from NT-001 trial of personal Mon, 13 May 2019 08:00:00 -0400 Neon Therapeutics News Releases 7111 Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-present-bank-america-merrill-lynch-2019-health CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of America Merrill Lynch 2019 Wed, 08 May 2019 08:00:00 -0400 Neon Therapeutics News Releases 7106 Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-announces-completion-enrollment-phase-1b-nt First Clinical Trial to Evaluate the Potential of the Personal Neoantigen Vaccine NEO-PV-01 in Combination with Standard of Care in First-Line Metastatic NSCLC Treatment Setting CAMBRIDGE, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. Mon, 08 Apr 2019 07:00:00 -0400 Neon Therapeutics News Releases 7086 Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-presents-updated-data-ongoing-phase-1b-nt-001 Post-Vaccine Immune and Pathologic Markers Associated with Durable Clinical Benefit in Metastatic Melanoma Patient Cohort Top-line Results, Including 52-Week Clinical Outcomes, from Full NT-001 Trial in Melanoma, Non-Small Cell Lung and Bladder Cancers Expected Later in 1H 2019 CAMBRIDGE, Mass. Sun, 31 Mar 2019 15:00:00 -0400 Neon Therapeutics News Releases 7061 Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-reports-fourth-quarter-and-full-year-2018 CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and provided a business Mon, 11 Mar 2019 03:00:00 -0400 Neon Therapeutics News Releases 7031 Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-present-cowen-and-company-39th-annual-health CAMBRIDGE, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Cowen and Company 39 th Annual Mon, 04 Mar 2019 08:00:00 -0500 Neon Therapeutics News Releases 7021 Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-present-american-association-cancer-research CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place Wed, 27 Feb 2019 19:25:00 -0500 Neon Therapeutics News Releases 6986 Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-present-8th-annual-leerink-partners-global CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the 8th Annual Leerink Partners Global Thu, 21 Feb 2019 08:00:00 -0500 Neon Therapeutics News Releases 6971 Neon Therapeutics Provides Business Update and Outlook for 2019 https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-provides-business-update-and-outlook-2019 CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a business update and outlook for 2019. “We have an exciting year ahead of us in 2019, with multiple data Thu, 03 Jan 2019 07:00:00 -0500 Neon Therapeutics News Releases 6941 Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma https://ir.neontherapeutics.com/news-releases/news-release-details/neon-therapeutics-and-apexigen-announce-first-patient-dosed CAMBRIDGE, Mass. and SAN CARLOS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, and Apexigen, Inc. , a clinical-stage biopharmaceutical company, today announced that patient dosing Thu, 06 Dec 2018 07:00:00 -0500 Neon Therapeutics News Releases 6936